Dyslipidemia refers to abnormalities in the composition, concentration, or size of lipids and lipoproteins in the circulation, and it is a key modifiable risk factor for cardiovascular (CV) disease. With respect to lipid-modifying therapies, the greatest commercial success has come via agents reducing low-density lipoprotein (LDL)-cholesterol, but research and development focusing on triglycerides, high-density lipoprotein (HDL)-cholesterol, and other novel biomarkers is ongoing, with the aim of ultimately providing CV benefits. During the 2017-2027 forecast period, the dyslipidemia market is expected to have two distinct phases: 1) early contraction owing largely to the genericization of the dominant statin class, and 2) marked growth due to the emergence of novel therapies, including Amgen’s Repatha, Sanofi/Regeneron Pharmaceuticals’ Praluent, Amarin’s Vascepa, Kowa Pharmaceuticals’ Parmodia (pemafibrate), The Medicines Company/Alnylam Pharmaceuticals’ inclisiran, Esperion Therapeutics’ bempedoic acid, and AstraZeneca’s Epanova.
Questions Answered:
Product Description:
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.